Clinical Trial Update: DapagliFLOzin in Renal AL Amyloidosis (FLORAL) [Phase 2]

View source ↗

Summary

A Phase 2 trial called FLORAL is evaluating the SGLT2 inhibitor dapagliflozin in light-chain (AL) amyloidosis with renal involvement. The study is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Light-chain Amyloidosis

Drugs mentioned

• Dapagliflozin (dapagliflozin)

Snippet

Sponsor: Barbara Ann Karmanos Cancer Institute | Conditions: Renal AL Amyloidosis | Phase 2 | Status: RECRUITING